229 related articles for article (PubMed ID: 19464560)
1. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.
Kopecky-Bromberg SA; Fraser KA; Pica N; Carnero E; Moran TM; Franck RW; Tsuji M; Palese P
Vaccine; 2009 Jun; 27(28):3766-74. PubMed ID: 19464560
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
3. Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.
Hung JT; Tsai YC; Lin WD; Jan JT; Lin KH; Huang JR; Cheng JY; Chen MW; Wong CH; Yu AL
Antiviral Res; 2014 Jul; 107():110-8. PubMed ID: 24786174
[TBL] [Abstract][Full Text] [Related]
4. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
[TBL] [Abstract][Full Text] [Related]
5. α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice.
Li K; Luo J; Wang C; He H
Vaccine; 2011 Oct; 29(44):7711-7. PubMed ID: 21839133
[TBL] [Abstract][Full Text] [Related]
6. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs.
Dwivedi V; Manickam C; Dhakal S; Binjawadagi B; Ouyang K; Hiremath J; Khatri M; Hague JG; Lee CW; Renukaradhya GJ
Vet Microbiol; 2016 Apr; 186():157-63. PubMed ID: 27016770
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
9. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
Youn HJ; Ko SY; Lee KA; Ko HJ; Lee YS; Fujihashi K; Boyaka PN; Kim SH; Horimoto T; Kweon MN; Kang CY
Vaccine; 2007 Jul; 25(28):5189-98. PubMed ID: 17548137
[TBL] [Abstract][Full Text] [Related]
10. Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs.
Artiaga BL; Morozov I; Ransburgh R; Kwon T; Balaraman V; Indran SV; De Carvalho Madrid DM; Gu W; Henningson J; Ma W; Richt JA; Driver JP
Anim Dis; 2022; 2(1):19. PubMed ID: 35936354
[TBL] [Abstract][Full Text] [Related]
11. Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge.
Wang X; Zhang W; Liu F; Zheng M; Zheng D; Zhang T; Yi Y; Ding Y; Luo J; Dai C; Wang H; Sun B; Chen Z
Arch Virol; 2012 Aug; 157(8):1451-61. PubMed ID: 22552485
[TBL] [Abstract][Full Text] [Related]
12. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
[TBL] [Abstract][Full Text] [Related]
13. A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine.
Feng H; Sun R; Song G; Zhu S; Nie Z; Lin L; Yi R; Wu S; Wang G; He Y; Wang S; Wang P; Wu L; Shu J
Viruses; 2022 May; 14(6):. PubMed ID: 35746644
[TBL] [Abstract][Full Text] [Related]
14. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
[TBL] [Abstract][Full Text] [Related]
15. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.
Gonzalez-Aseguinolaza G; Van Kaer L; Bergmann CC; Wilson JM; Schmieg J; Kronenberg M; Nakayama T; Taniguchi M; Koezuka Y; Tsuji M
J Exp Med; 2002 Mar; 195(5):617-24. PubMed ID: 11877484
[TBL] [Abstract][Full Text] [Related]
16. Augmenting Influenza-Specific T Cell Memory Generation with a Natural Killer T Cell-Dependent Glycolipid-Peptide Vaccine.
Anderson RJ; Li J; Kedzierski L; Compton BJ; Hayman CM; Osmond TL; Tang CW; Farrand KJ; Koay HF; Almeida CFDSSE; Holz LR; Williams GM; Brimble MA; Wang Z; Koutsakos M; Kedzierska K; Godfrey DI; Hermans IF; Turner SJ; Painter GF
ACS Chem Biol; 2017 Nov; 12(11):2898-2905. PubMed ID: 29043774
[TBL] [Abstract][Full Text] [Related]
17. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.
Kamijuku H; Nagata Y; Jiang X; Ichinohe T; Tashiro T; Mori K; Taniguchi M; Hase K; Ohno H; Shimaoka T; Yonehara S; Odagiri T; Tashiro M; Sata T; Hasegawa H; Seino KI
Mucosal Immunol; 2008 May; 1(3):208-18. PubMed ID: 19079180
[TBL] [Abstract][Full Text] [Related]
19. Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection.
Kim YH; Bang YJ; Park HJ; Li Ko H; Park SI; Hwang KA; Kim H; Nam JH
Vaccine; 2020 Sep; 38(39):6141-6152. PubMed ID: 32739118
[TBL] [Abstract][Full Text] [Related]
20. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.
Mayrhofer J; Coulibaly S; Hessel A; Holzer GW; Schwendinger M; Brühl P; Gerencer M; Crowe BA; Shuo S; Hong W; Tan YJ; Dietrich B; Sabarth N; Savidis-Dacho H; Kistner O; Barrett PN; Falkner FG
J Virol; 2009 May; 83(10):5192-203. PubMed ID: 19279103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
